| Previous Close | 32.89 |
| Open | 32.79 |
| Bid | 33.03 x 200 |
| Ask | 33.17 x 400 |
| Day's Range | 32.69 - 33.00 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 16,657,605 |
| Avg. Volume | 20,276,650 |
| Market Cap | 196.94B |
| Beta | 1.07 |
| PE Ratio (TTM) | 27.78 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.87%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- The Wall Street Journal•5 hours ago
[$$] United Therapeutics in Settlement Talks With Justice Department
United Therapeutics has set aside $210 million for a possible settlement of a U.S. Justice Department investigation of whether the company’s contributions to patient-assistance charity groups violate federal ...
- Financial Times•6 hours ago
[$$] AstraZeneca: transcendental agitation
Philosopher Blaise Pascal never faced proof he was wrong to believe in God. AstraZeneca's Pascal Soriot has discovered his faith in the Mystic cancer drug trial really was misplaced. A failure of a key ...
- InvestorPlace•9 hours ago
Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally
For the past few months, Gilead Sciences, Inc. (NASDAQ:GILD) could not fulfill the technical upside promise. Last night, GILD report earnings and the stock is spiking toward $76. Click to Enlarge Coming into the earnings, sentiment had also shifted in favor of better days to come from GILD stock, and I am one who likes to trade with the market sentiment.
